Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as rhPTH(1-34)
rhPTH · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| rhPTH(1-34) | DRUG | - |
| SB-751689 100 mg | DRUG | - |
| SB-751689 400 mg | DRUG | - |
Inclusion Criteria: * Healthy postmenopausal women 40 to 65 years of age, inclusive, meeting at least one of the following: Postmenopausal defined by the STRAW criteria of 12 months of spontaneous amenorrhea with serum FSH levels = 40 mIU/mL; History of bilateral oophorectomy (with or without hyste...
rhPTH is an investigational recombinant parathyroid hormone developed by GSK plc for osteoporosis. It is also known as rhPTH(1-34). It has been studied in a Phase 1 trial evaluating its effects on calcium and phosphate excretion in women. It is not approved and remains in clinical development.
rhPTH has been studied for osteoporosis, a condition of reduced bone density. The single Phase 1 trial enrolled 40 women aged 40 years and older and examined the drug's effects on calcium and phosphate excretion. It is investigational and has not been approved for osteoporosis or any other indication.
rhPTH is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 1 study of rhPTH(1-34) conducted in the United States. GSK is the developer associated with this asset.
rhPTH is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The study was randomized but not double blind and used an uncontrolled design. rhPTH is investigational and has not received FDA approval.
rhPTH has been evaluated in one completed Phase 1 trial, NCT00532077, titled a study to evaluate the effects of SB-751689 or rhPTH(1-34) on excretion of calcium and phosphate in women. It enrolled 40 female participants aged 40 years and older in the United States. No trials are currently active.
Yes, rhPTH and rhPTH(1-34) refer to the same investigational compound developed by GSK plc. The designation rhPTH(1-34) appears in the trial title for NCT00532077, which studied the drug in women with osteoporosis. Both names describe the same asset.